For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Apellis Pharmaceuticals Inc’s stock clocked out at $25.17, up 0.80% from its previous closing price of $24.97. In other words, the price has increased by $0.80 from its previous closing price. On the day, 2.26 million shares were traded. APLS stock price reached its highest trading level at $25.37 during the session, while it also had its lowest trading level at $24.5648.
Ratios:
To gain a deeper understanding of APLS’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.63 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 40.50. For the most recent quarter (mrq), Quick Ratio is recorded 3.10 and its Current Ratio is at 3.54. In the meantime, Its Debt-to-Equity ratio is 1.18 whereas as Long-Term Debt/Eq ratio is at 0.93.
On October 15, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $32.
Goldman Downgraded its Neutral to Sell on September 26, 2025, while the target price for the stock was maintained at $18.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 16 ’25 when Watson David O. sold 5,000 shares for $24.49 per share. The transaction valued at 122,450 led to the insider holds 103,730 shares of the business.
Watson David O. bought 5,000 shares of APLS for $122,450 on Dec 16 ’25. On Nov 17 ’25, another insider, Watson David O., who serves as the General Counsel of the company, sold 5,000 shares for $20.06 each. As a result, the insider received 100,300 and left with 108,730 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APLS now has a Market Capitalization of 3184639744 and an Enterprise Value of 3179781632. As of this moment, Apellis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 84.78. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.13 while its Price-to-Book (P/B) ratio in mrq is 7.94. Its current Enterprise Value per Revenue stands at 3.128 whereas that against EBITDA is 38.739.
Stock Price History:
The Beta on a monthly basis for APLS is 0.32, which has changed by -0.21748668 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, APLS has reached a high of $35.57, while it has fallen to a 52-week low of $16.10. The 50-Day Moving Average of the stock is 8.57%, while the 200-Day Moving Average is calculated to be 14.91%.
Shares Statistics:
It appears that APLS traded 2.63M shares on average per day over the past three months and 2429250 shares per day over the past ten days. A total of 126.50M shares are outstanding, with a floating share count of 103.76M. Insiders hold about 17.99% of the company’s shares, while institutions hold 99.29% stake in the company. Shares short for APLS as of 1765756800 were 17247829 with a Short Ratio of 6.55, compared to 1763078400 on 16349387. Therefore, it implies a Short% of Shares Outstanding of 17247829 and a Short% of Float of 17.940001.
Earnings Estimates
The market rating of Apellis Pharmaceuticals Inc (APLS) is currently shaped by the ongoing analysis conducted by 11.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.37 and low estimates of -$0.63.
Analysts are recommending an EPS of between $0.48 and $0.04 for the fiscal current year, implying an average EPS of $0.28. EPS for the following year is -$1.16, with 11.0 analysts recommending between -$0.09 and -$1.73.
Revenue Estimates
In. The current quarter, 19 analysts expect revenue to total $200.44M. It ranges from a high estimate of $232.4M to a low estimate of $184.82M. As of. The current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $212.53MFor the next quarter, 19 analysts are estimating revenue of $190.89M. There is a high estimate of $208.5M for the next quarter, whereas the lowest estimate is $174M.
A total of 20 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $1.05B, while the lowest revenue estimate was $988.69M, resulting in an average revenue estimate of $1.01B. In the same quarter a year ago, actual revenue was $781.37MBased on 20 analysts’ estimates, the company’s revenue will be $863.98M in the next fiscal year. The high estimate is $955M and the low estimate is $787.62M.
